kabutan

KAKEN PHARMACEUTICAL CO.,LTD.(4521) Summary

4521
TSE Prime
KAKEN PHARMACEUTICAL CO.,LTD.
4,195
JPY
-10
(-0.24%)
Apr 3, 3:30 pm JST
26.26
USD
Apr 3, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
69.0
PBR
1.09
Yield
4.53%
Margin Trading Ratio
6.68
Stock Price
Apr 3, 2026
Opening Apr 3, 9:00 am
4,190 JPY 26.27 USD
Previous Close Apr 2
4,205 JPY 26.39 USD
High Apr 3, 10:28 am
4,215 JPY 26.42 USD
Low Apr 3, 9:16 am
4,160 JPY 26.09 USD
Volume
79,900
Trading Value
0.34B JPY 2.10M USD
VWAP
4195.58 JPY 26.27 USD
Minimum Trading Value
419,500 JPY 2,626 USD
Market Cap
0.19T JPY 1.16B USD
Number of Trades
209
Liquidity & Number of Trades
As of Apr 3, 2026
Liquidity
Slightly High
1-Year Average
500
1-Year High Apr 9, 2025
2,521
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 27, 2026 55,000 52,900 0.96
Mar 19, 2026 51,100 52,400 1.03
Mar 13, 2026 53,400 52,900 0.99
Mar 6, 2026 61,500 41,400 0.67
Feb 27, 2026 52,200 71,100 1.36
Company Profile
KAKEN PHARMACEUTICAL CO.,LTD. is a mid-sized pharmaceutical company. Its main products include joint function improvement agents and onychomycosis medications. The company also develops generic drugs and agricultural chemicals.
Sector
Pharmaceuticals
KAKEN PHARMACEUTICAL CO.,LTD. primarily engages in the pharmaceutical business, manufacturing and selling pharmaceuticals, medical devices, and agricultural chemicals. The company operates as a group that includes itself and two consolidated subsidiaries. In the pharmaceutical segment, Kaken Pharma and Asam handle manufacturing and sales. Additionally, the company is involved in the real estate business. The group as a whole focuses on the medical field while diversifying into areas such as agriculture. As a mid-sized player in the pharmaceutical industry, KAKEN PHARMACEUTICAL CO.,LTD. has established a unique product lineup and business structure, with its main products including the joint function improvement agent "ARTZ" and the onychomycosis treatment "Clenafin."